Markets

Teva Pharmaceutical Industries Limited (TEVA): How Do the Books Stack Up?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) seems to be forming a pattern of major movements, providing only some crumbs of outlook for market participants trying to figure out its next move. Now trading with a market value of 24.14B, the company has a mix of catalysts and obstacles that spring from the nature of its operations. Everyone seems to have their own opinion of this stock. But what do the numbers really say? We think it’s a great time to take a fresh look.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For TEVA, the company currently has 1.86 billion of cash on the books, which is offset by 2.92 billion in current liabilities. The trend over time is important to note. In this case, the company’s debt has been falling. The company also has 0 in total assets, balanced by 2.86 billion in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Teva Pharmaceutical Industries Limited saw 0 in free cash flow last quarter, representing a quarterly net change in cash of 1.36 billion. Perhaps most importantly where cash movements are concerned, the company saw about 0 in net operating cash flow.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 4.7 billion in total revenues. That represents a quarterly year/year change in revenues of -0.22% in sequential terms, the TEVA saw sales grow by -0.08%.



But what about the bottom line? After all, that’s what really matters in the end. Teva Pharmaceutical Industries Limited is intriguing when broken down to its core data. The cost of selling goods last quarter was 2.64 billion, yielding a gross basic income of 2.06 billion. For shareholders, given the total diluted outstanding shares of 1.05B, this means overall earnings per share of -160. Note, this compares with a consensus analyst forecast of 0.50 in earnings per share for its next fiscal quarterly report.

Is Teva Pharmaceutical Industries Limited (NYSE:TEVA) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about 2.73 in total earnings per share. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Teva Pharmaceutical Industries Limited.

Previous ArticleNext Article

Related Post

Looking at the Big Picture for Goldcorp Inc. (GG) Goldcorp Inc. (NYSE:GG) has recently been identified as an interesting stock but more in-depth monitoring is needed for a trade decision. Now trading ...
How Does the Fundamental Picture Look for Fitbit, ... Fitbit, Inc. (NYSE:FIT) has recently been identified as an interesting stock but more in-depth monitoring is needed for a trade decision. Now trading ...
Taking a Look at the Operational Data for Snap Inc... Snap Inc. (NYSE:SNAP) is an interesting stock at present. Now trading with a market value of 9.09B, the company has a mix of catalysts and obstacles t...
Old Republic International Corporation (ORI) Makes... Old Republic International Corporation (NYSE:ORI) trade is getting exciting but lets take a deeper look whether it is as good a moment. Now trading wi...
Taking a Look at the Operational Data for Rowan Co... Rowan Companies plc (NYSE:RDC) is on our radar right now but there could still be some opportunities on the horizon. Now trading with a market value o...